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31Comparison of Sirolimus-Eluting Stenting With
Minimally Invasive Bypass Surgery for Stenosis of
the Left Anterior Descending Coronary Artery
7-Year Follow-Up of a Randomized TrialABSTRACTOBJECTIVES The aim of this analysis was to assess the 7-year long-term safety and effectiveness of a randomized
comparison of percutaneous coronary intervention (PCI) with sirolimus-eluting stents (SES) versus minimally invasive
direct coronary artery bypass (MIDCAB) surgery for the treatment of isolated proximal left anterior descending
lesions.
BACKGROUND Long-term follow-up data comparing PCI by SES and MIDCAB surgery for isolated proximal left anterior
descending lesions are sparse.
METHODS Patients were randomized either to PCI with SES (n ¼ 65) or MIDCAB (n ¼ 65). Follow-up data were obtained
after 7 years with respect to the primary composite endpoint of death, myocardial infarction, and target vessel revas-
cularization. Angina was assessed by the Canadian Cardiovascular Society classiﬁcation and quality of life with Short Form
36 and MacNew quality of life questionnaires.
RESULTS Follow-up was conducted in 129 patients at a median time of 7.3 years (interquartile range: 5.7, 8.3). There
were no signiﬁcant differences in the incidence of the primary composite endpoint between groups (22% PCI vs. 12%
MIDCAB; p ¼ 0.17) or the endpoints death (14% vs. 17%; p ¼ 0.81) and myocardial infarction (6% vs. 9%, p ¼ 0.74).
However, the target vessel revascularization rate was higher in the PCI group (20% vs. 1.5%; p < 0.001). Clinical
symptoms and quality of life improved signiﬁcantly from baseline with both interventions and were similar in magnitude
between groups.
CONCLUSIONS At 7-year follow-up, PCI by SES andMIDCAB in isolated proximal left anterior descending lesions yielded
similar long-term outcomes regarding the primary composite clinical endpoint and quality of life. Target vessel revascu-
larization was more frequent in the PCI group. (MIDCAB Versus DES in Proximal LAD Lesions; NCT00299429) (J Am Coll
Cardiol Intv 2015;8:30–8) © 2015 by the American College of Cardiology Foundation.C linical prognosis in patients with untreatedhigh-grade proximal stenosis of the left an-terior descending (LAD) artery is poor due
to the large territory of myocardium at risk (1,2).
Established treatment options in isolated severe ste-
nosis of the proximal LAD comprise bypass grafting
by minimally invasive direct coronary artery by-
pass (MIDCAB) surgery and percutaneous coronary
intervention (PCI) either with bare-metal (BMS) or
drug-eluting stents (DES) (3–5). At long-term
follow-up, BMS in proximal LAD disease had a
higher target vessel revascularization (TVR) rate in
comparison to MIDCAB surgery, whereas the inci-
dence of more critical endpoints such as myocardial
infarction and death was similar (6,7). The risk of in-
stent restenosis and TVR could be reduced with theuse of DES instead of BMS (8). We previously pre-
sented 12 month results of the only randomized
comparison of PCI with sirolimus-eluting stents
(SES) to MIDCAB surgery for isolated proximal le-
sions of the LAD showing noninferiority of the
percutaneous approach (9). To further elucidate
long-term advantages or disadvantages of PCI with
SES in comparison to MIDCAB surgery, we hereby
present the 7-year follow-up of this randomized,
prospective trial (9).
METHODS
The detailed design of this trial has been described
previously (9). In summary, symptomatic patients
with compatible symptoms and/or documented
ABBR EV I A T I ON S
AND ACRONYMS
BMS = bare-metal stent(s)
CI = conﬁdence interval(s)
DES = drug-eluting stent(s)
HR = hazard ratio(s)
IQR = interquartile range
LAD = left anterior descending
MACE = major adverse cardiac
events
MIDCAB = minimally invasive
direct coronary artery bypass
PCI = percutaneous coronary
intervention
SES = sirolimus-eluting
stent(s)
SF-36 = Short Form 36
TVR = target vessel
revascularization
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32myocardial ischemia and isolated high-grade
lesions (>50% diameter stenosis) of the
proximal LAD were included. A consensus on
patient eligibility had to be obtained from
both the cardiac surgeon and the cardiologist
before randomization. After written
informed consent, balanced randomization
via sealed envelopes was performed, assign-
ing patients to PCI by SES (Cypher, Cordis,
Langenfeld, Germany) or MIDCAB surgery.
Exclusion criteria were acute coronary
syndromes requiring immediate interven-
tion, additional valvular heart disease
requiring treatment, previous interventional
or surgical treatment for coronary artery or
valvular disease, severe peripheral arterial
disease, signiﬁcant carotid stenosis requiring
treatment, renal dysfunction requiring dial-
ysis, any diseases with limited life expec-
tancy, overt congestive heart failure, uppergastrointestinal bleeding <4 weeks, contraindication
to antiplatelet therapy, and extreme obesity (due to
MIDCAB surgery preclusion).
Angiographic exclusion criteria were total occlu-
sions, involvement of the left main stem, stenosis of
the ﬁrst diagonal branch, intramyocardial course of
the LAD, stenosis extending over a major diagonal
branch (>1.5 mm), and stenosis at any other location
requiring treatment. The study was approved by the
institutional ethics committee and all patients gave
written informed consent.
STENTING PROCEDURE. Stenting with SES was per-
formed according to standard practice (9). Patients
received aspirin 100 mg/d indeﬁnitely and clopidog-
rel 75 mg/d for 12 months following a loading dose of
600 mg before the procedure.
MINIMALLY INVASIVE DIRECT CORONARY ARTERY
BYPASS SURGERY. Standard MIDCAB surgery was
performed through a left anterolateral minithor-
acotomy on the beating heart without cardiopulmo-
nary bypass under general anesthesia (9). The left
internal thoracic artery was used as bypass graft.
Aspirin (100 mg/d) treatment was recommended
indeﬁnitely.
FOLLOW-UP. At 7 years, data were collected by a
structured patient interview including assessment of
clinical endpoints, anginal symptoms, and quality of
life. Reported clinical events were conﬁrmed by
contact with the general practitioner, referring
cardiologist, and/or the treating hospital. Death was
deﬁned as death from any cause. Death was regarded
as cardiac in origin unless obvious noncardiac causescould be identiﬁed. In case of any doubt, death was
counted as cardiac. For myocardial infarction, the
universal deﬁnition of myocardial infarction criteria
was applied (10).
The initial study protocol mandated a complete
clinical work-up, including symptom-limited exercise
stress test and invasive coronary angiography at
12-month follow-up. During the subsequent course,
further noninvasive or invasive studies were only
performed if clinically indicated due to symptoms or
objective ischemia. Repeated interventions were
therefore clinically driven and performed only in case
of recurrence of angina and/or a positive stress test.
For survival analysis, data until their last known
status were used.
All events were adjudicated by a blinded event
committee consisting of an experienced cardiologist
and cardiovascular surgeon.
ENDPOINTS. The primary composite endpoint was
freedom from major adverse cardiovascular events
(MACE), deﬁned as death from any cause, myocardial
infarction, and the need for repeated TVR. Secondary
endpoints were each individual component of the
primary endpoint. For the combined MACE rate, to
avoid double counting of patients with more than 1
event, each patient contributed only once to the
composite MACE endpoint and the ﬁrst occurring
event was counted regardless of severity.
QUALITY OF LIFE. Quality of life was assessed by 2
standard questionnaires. The Short Form 36 (SF-36) is
a 36-item test evaluating 8 dimensions of health
including: limitations in physical functioning; usual
role activities; social functioning related to health
problems; and vitality. Furthermore, it provides a
global evaluation of health. Each dimension is scored
on a scale from 0 to 100 (11).
Additionally, health-related quality of life was
assessed using the MacNew Quality of Life Ques-
tionnaire, which is speciﬁcally designed for patients
with heart disease. It involves 27 items with 3 sub-
scales (emotional, physical, and social) and a global
scale (12). In both tests, higher scores indicate higher
quality of life.
Anginal symptoms were assessed by the Canadian
Cardiovascular Society classiﬁcation and the use of
antianginal drugs such as nitrates, ranolazine, or
ivabradine was recorded.
STATISTICAL ANALYSIS. All analyses were per-
formed according to the intention-to-treat principle.
Patients lost to follow-up were excluded in the anal-
ysis. Categorical variables are expressed as number
TABLE 1 MACE at Long-Term Follow-Up (7 Years)
SES
(n ¼ 64)
MIDCAB
(n ¼ 65) p Value
Relative Risk
(95% CI)
All-cause death, myocardial infarction,
or target vessel revascularization
(primary endpoint)
14 (22) 8 (12) 0.17 1.47 (0.82–2.62)
All-cause death 9 (14) 11 (17) 0.81 0.91 (0.58–1.39)
Cardiac death 2 (3) 1 (1.5) 0.62 1.52 (0.31–7.62)
Myocardial infarction 4 (6) 6 (9) 0.74 0.83 (0.48–1.41)
Cardiac death or myocardial infarction 4 (6) 7 (11) 0.53 0.77 (0.48–1.25)
Target vessel revascularization 13 (20) 1 (1.5) <0.001 7.79 (1.17–51.87)
Values are n (%) per clinical event category.
CI ¼ conﬁdence interval; MACE ¼ major adverse cardiovascular events; MIDCAB ¼ minimally invasive direct
coronary artery bypass; SES ¼ sirolimus-eluting stent(s).
FIGURE 1 Trial Proﬁle
Trial proﬁle and trial ﬂow. IQR ¼ interquartile range; MIDCAB ¼ minimally invasive direct
coronary artery bypass surgery; SES ¼ sirolimus-eluting stent(s).
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33and percent of patients. Continuous variables are
reported as mean  SD or median and interquartile
range (IQR) according to their distribution. Values
between groups were compared by unpaired Student
t-test after testing for normal distribution; otherwise,
nonparametric Mann-Whitney U tests were used.
Fisher exact or chi-square tests were used for cate-
gorical variables with nominal scales. Values across
time were compared by paired t-tests or nonpara-
metric Wilcoxon tests.
For clinical endpoints, the Kaplan-Meier method
was applied, and differences were assessed by the
log-rank test. Hazard ratios and their 95% conﬁdence
intervals (CIs) were calculated according to Klein (13).
For quality of life endpoints, a mixed model for
repeated measures was used to compare sirolimus-
eluting stenting and MIDCAB surgery at 12-month to
7-year follow-up on SF-36 and MacNew domains. For
intragroup comparison, paired t-tests or nonpara-
metric Wilcoxon rank sum tests were used.
Additionally, exploratory landmark analyses using
the Kaplan-Meier method were performed for the
primary composite endpoint and TVR. The landmark
was chosen at 12 months and therefore the ﬁrst
analysis covers the period from 0 to 12 months and
the second the period from 12 months to 7 years.
Detailed results in the time frame 0 to 12 months have
been published previously (9). Any patient with an
event prior to the 12-month landmark was excluded
from further analysis for the second period regarding
the composite endpoint. For the TVR landmark
analysis, those patients with previous TVR or death
where excluded.
The statistical analyses were conducted with the
use of SPSS (version 17.0, SPSS Inc., Chicago, Illinois).
A 2-tailed probability value of p < 0.05 was consid-
ered statistically signiﬁcant.
RESULTS
Between January 1, 2003 and October 31, 2007, 213
patients with isolated proximal LAD stenosis were
screened for inclusion into the trial. Of these, 130
patients met the inclusion and exclusion criteria and
were randomized to revascularization either by
MIDCAB surgery (n ¼ 65) or stenting (n ¼ 65). All
patients received the assigned treatment. The long-
term follow-up was completed for 129 patients
(99.3%) with a median follow-up of 7.3 years
(IQR: 5.7 to 8.3 years). One patient in the PCI group
was lost to follow-up; despite intensive efforts, no
information could be obtained (Figure 1).
Baseline characteristics and angiographic charac-
teristics were not signiﬁcantly different between thetreatment groups and have been published previ-
ously (9).
PRIMARY COMPOSITE ENDPOINT. In both the binary
event and the time-to-event analysis at 7 years, there
were no signiﬁcant differences with regard to the
combined primary endpoint between PCI with SES
and MIDCAB surgery (hazard ratio [HR]: 1.70, 95% CI:
0.71 to 4.05; p ¼ 0.23) (Table 1, Figure 2A).
Landmark analyses showed no statistically signiﬁ-
cant differences between groups with regard to the
primary endpoint during the ﬁrst 12 months (HR: 1.23,
95% CI: 0.33 to 4.57; p ¼ 0.75) and the time frame
from 12 months to 7 years (HR: 2.26, 95% CI 0.71 to
7.24; p ¼ 0.16) (Figure 2B).
The binary incidence of the individual endpoints at
7-year follow-up are shown in Table 1.
FIGURE 2 Freedom From Combined Primary Study Endpoint
Kaplan-Meier curve showing freedom from major adverse cardiovascular events during 7 years of follow-up (A); time frame 0 to 12 months and 1 to 7 years (B).
The dotted black line in B represents the 12-month landmark. Abbreviations as in Figure 1.
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34SECONDARY ENDPOINTS. Revascular izat ion . In the
PCI group, the need for TVR at 7 years was signiﬁ-
cantly higher than for the MIDCAB group (time-to-
event analysis: HR: 13.50, 95% CI: 1.76 to 103.29;
p < 0.001) (Table 1, Figure 3A).
Landmark analyses revealed a higher rate of TVR in
the PCI group in the time frame 12 months to 7 years
(HR: 8.2, 95% CI: 1.03 to 66.37; p ¼ 0.02) (Figure 3B).
Overall, in the interventional group, a total of 17
TVR were performed in 13 patients with the following
methods: 2 drug-eluting balloons; 3 BMS; 8 DES; 2
MIDCAB in single vessel disease; and 2 coronary ar-
tery bypass grafts in multivessel disease.In the surgical group, 1 patient required TVR via
PCI with 1 DES at long-term 7-year follow-up.
Death and myocard ia l in farct ion. All-cause mor-
tality did not differ between the 2 treatment groups
at 7-year follow-up (PCI 14% vs. MIDCAB 17%;
p ¼ 0.81) (Table 1). In addition, cardiac death rates
were similar (Table 1). Cardiac deaths in the stenting
group included 1 death due to congestive heart
failure and 1 death due to myocardial infarction. One
patient in the surgery group died of sudden cardiac
death.
The rate of myocardial infarctions was not statis-
tically different between stenting and surgery at
FIGURE 3 Freedom From TVR
Kaplan-Meier curve showing freedom from target vessel revascularization (TVR) during 7 years of follow-up (A); time frame 0 to 12 months and 1 to 7 years (B). The
dotted black line in B represents the 12-month landmark. Abbreviations as in Figure 1.
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357-year follow-up (time-to-event analysis: HR: 0.56,
95% CI: 0.16 to 2.03; p ¼ 0.38). Landmark analysis
showed no statistically signiﬁcant differences be-
tween groups for the period 12 months to 7 years (HR:
1.08, 95% CI: 0.18 to 6.57; p ¼ 0.93).
No acute, subacute, or late stent thromboses were
observed at long-term follow-up in the PCI group.
Angina l symptoms and ant iang ina l medicat ion .
One patient in each group passed away shortly after
completing the 7-year follow-up questionnaire. These
patients were included in the analysis of anginal
symptoms, medication, and quality of life.After PCI, the Canadian Cardiovascular Society
classiﬁcation score at 12 months was 0 (IQR: 0 to 1) and
at 7 years was 0 (IQR: 0 to 2) (p ¼ 0.07 for the compar-
ison with 12-months follow-up). Overall, 75% of the
patients were completely free from angina at 7-year
follow-up.
In the MIDCAB group, the median angina class
was 0 (IQR: 0 to 1) at 12-month and 0 (IQR: 0 to 1) at 7-
year follow-up (p ¼ 0.92 for the comparison with
12-months follow-up), with 86% of patients free of
anginal symptoms (p ¼ 0.24 for the intergroup
comparison).
TABLE 2 Cardiovascular Medication and CCS Classes at
Long-Term Follow-Up
SES
(n ¼ 55)
MIDCAB
(n ¼ 54) P Value
Beta-blocker 49 (89) 51 (94) 0.51
ACE-inhibitor/AT-1 antagonist 43 (78) 40 (74) 0.65
Statin 43 (78) 40 (74) 0.65
Aspirin 43 (78) 42 (78) 1.00
Thienopyridines 6 (11) 1 (2) 0.11
Antianginal medication 8 (15) 4 (7) 0.36
Calcium channel antagonists 13 (24) 8 (15) 0.33
Diuretic agents 24 (44) 25 (46) 0.84
Antidiabetics 16 (29) 11 (20) 0.37
Oral anticoagulation 7 (13) 6 (11) 1.00
CCS class 0.24
0 29 (53) 31 (56)
1 12 (22) 16 (30)
2 13 (24) 5 (9)
3 0 1 (2)
4 1 (2) 2 (4)
Values are n (%).
ACE ¼ angiotensin-converting enzyme; AT ¼ angiotensin; CCS ¼ Canadian
Cardiovascular Society; other abbreviations as in Table 1.
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36There were no signiﬁcant differences between
groups at 7-year follow-up with regard to cardio-
vascular medications including antianginal agents
(Table 2).
Qual i ty of l i fe . One patient in each group passed
away 1 2 months, respectively, after completingTABLE 3 Quality of Life Assessed by SF-36 and MacNew Comparing 1
SES p Val
12 Months 7 Years
n 65 56
SF-36
Physical functioning 19.26  4.0 19.14  4.0
Role—physical 14.43  3.9 15.43  4.8
Bodily pain 3.85  2.0 4.27  2.2
General health 16.51  2.0 17.89  2.6
Vitality 12.22  1.8 12.38  1.8
Social functioning 5.72  0.8 5.96  0.5
Role—emotional 11.54  2.9 12.21  3.5
Mental health 16.63  2.1 17.11  1.8
Physical component summary 54.05  6.0 56.73  6.9
Mental component summary 46.11  5.3 47.66  5.1
MacNew
Emotional 5.42  0.9 5.88  0.9
Physical 5.57  0.9 5.93  0.9
Social 5.69  0.9 6.20  0.8
Total 5.56  0.9 6.00  0.8
Values are mean  SD.
SF-36 ¼ Short Form 36; other abbreviations as in Table 1.the 7-year follow-up quality of life questionnaire
resulting in 56 completed questionnaires (86%) in the
PCI group and 55 (85%) in the MIDCAB group.
The treatment effect of stenting and surgery on
changes in the perceived quality of life from the
12-month to 7-year follow-up is displayed in Table 3.
There were no signiﬁcant differences in SF-36 and
MacNew domains between groups.
However, patients after both stenting and surgery
showed a signiﬁcant improvement from short-term to
long-term follow-up in nearly all domains. Only
the physical functioning domain in the SF-36 ques-
tionnaire declined in comparison to the 12-month
follow-up.
DISCUSSION
To the best of our knowledge, this is the only pro-
spective, randomized study with long-term results at
7 years in patients with isolated lesions of the prox-
imal LAD treated by either PCI with SES or MIDCAB
surgery. There were no signiﬁcant differences in the
composite primary endpoint and individual “hard”
endpoints such as cardiac death and myocardial
infarction between PCI with SES and MIDCAB. How-
ever, TVR was more frequent with PCI.
Current guidelines for revascularization of stable
coronary artery disease recommend a stop of the
procedure and discussion of further therapy with the
patient and the heart team, after the discovery of an2-Months and 7-Years Follow-Up
ue Intragroup MIDCAB p Value Intragroup
SES 12 Months 7 Years MIDCAB 7 Years
56 63 55 55 —
0.385 19.78  4.0 18.82  4.8 0.026 0.86
0.464 14.21  4.1 15.89  5.0 0.012 0.96
0.278 4.17  2.1 4.27  2.1 0.299 0.89
<0.001 16.35  2.4 17.58  2.6 0.004 0.84
0.591 12.14  1.9 12.95  2.1 0.064 0.29
0.063 5.90  0.9 6.00  0.4 0.423 0.25
0.342 11.51  3.1 13.00  2.8 0.006 0.43
0.314 16.56  2.5 17.87  0.19 0.003 0.29
0.034 54.51  6.0 56.56  8.7 0.141 0.96
0.107 46.11  5.5 49.82  4.4 <0.001 0.17
0.004 5.41  1.1 5.92  0.8 0.001 0.99
0.051 5.53  1.1 6.06  0.7 <0.001 0.75
0.003 5.68  1.0 6.41  0.7 <0.001 0.49
0.007 5.54  1.0 6.13  0.7 <0.001 0.73
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 , 2 0 1 5 Blazek et al.
J A N U A R Y 2 0 1 5 : 3 0 – 8 DES Versus MIDCAB Surgery in Proximal LAD
37isolated proximal LAD stenosis. In American guide-
lines, revascularization in patients with single-vessel
disease and an isolated proximal LAD stenosis PCI has
a Class IIb Level of Evidence: B recommendation and
surgery with left internal mammary artery a Class IIa
B recommendation, whereas in European guidelines
PCI has a Class IIa Level of Evidence: B recommen-
dation and surgery a Class I Level of Evidence: A
recommendation (14,15).
The lack of a signiﬁcant difference in mortality or
myocardial infarction rates between PCI and surgery
observed in the present study is in line with another
registry trial with propensity scoring comparing DES
with MIDCAB in patients with isolated proximal LAD
coronary artery lesions (16). Furthermore, the rate of
MACE in the PCI group was similar to a retrospective
study comparing different types of DES to BMS in
proximal LAD lesions. Of note, no differences in
MACE rates could be detected between ﬁrst- and
second-generation DES (8).
A large prospective, multicenter, observational
study with 3,067 patients using a biolimus-coated
stent compared those patients with a proximal LAD
stenosis (n ¼ 834, 27.2%) with patients who received
stenting at a nonproximal LAD location (n ¼ 2,203,
71.8%). After 2 years of follow-up, event rates in both
groups were similar (proximal LAD vs. other location:
MACE 7.67% vs. 6.45%, p ¼ 0.23; TVR 5.28% vs.
4.72%, p ¼ 0.51) (17).
Recently published data of the Swedish Coronary
Angiography and Angioplasty Registry (7,840 patients
with a proximal single-vessel coronary artery disease
with a follow-up of roughly 2 years) demonstrated that
proximal LAD lesions (n ¼ 4,476) had a higher reste-
nosis rate than did proximal left circumﬂex lesions
(n ¼ 1,294; HR: 2.28, 95% CI: 1.56 to 3.34; p< 0.001) but
not right coronary artery lesions (2,070 patients; HR:
0.94, 95% CI: 0.73 to 1.22; p ¼ 0.658). In comparison to
BMS, the use of DES resulted in lower restenosis rates
(HR: 0.39, 95% CI: 0.27 to 0.55; p < 0.001) and mor-
tality (HR: 0.58, 95% CI: 0.41 to 0.82; p ¼ 0.002) solely
in proximal LAD stenosis (18).
Long-term patency of internal mammary arterial
grafting and its superiority compared to vein grafts
anastomosed to the LAD in terms of survival, freedom
from infarction, angina, and repeated revasculariza-
tion could be observed in various trials (19–21).Relief of angina was preserved at 7-year long-term
follow-up, in comparison to 12-month follow-up, in
both groups. In the SES group, 75% of the patients
were free from angina and 86% in the MIDCAB group.
Other studies described similar relief of angina in the
range of 67% to 96% for PCI and 83% to 85% for
MIDCAB (7,22,23). For PCI in general, several studies
described a steady decline in quality of life at mid-
term follow-up in elderly patients after initial major
improvements (24–26). For MIDCAB studies, data on
quality of life at mid- to long-term follow-up are
scarce; 75 patients had similar quality of life
compared to an age-matched group after 1 year of
follow-up (27). The observed decline in physical
functioning in both groups is in line with another
study reﬂecting the reduction of general health due to
the advancement of age (28). However, the general
subjective quality of life has increased.
STUDY LIMITATIONS. As a result of the trial design,
blinding was not possible. The use of a ﬁrst-
generation DES may have led to a higher event rate
in the PCI group in comparison to a more contempo-
rary setting using second-generation DES. Due to the
relatively small sample size, the conﬁdence intervals
for the study endpoints, especially MACE and TVR are
wide, potentially masking any small but meaningful
differences in the endpoints. Another caveat is that
results are from a single high-volume tertiary care
center and may not be generalizable.
CONCLUSIONS
At 7-year follow-up, stenting with SES or MIDCAB
surgery for isolated proximal LAD lesions was asso-
ciated with similar long-term outcomes regarding
hard endpoints (all-cause and cardiac death as well as
myocardial infarction) and the combined composite
endpoint. However, a higher rate of TVR could be
observed. Quality of life and angina-free survival
were similar in both groups.
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